# Valbenazine Tosylate (Ingrezza)

Source: https://ourhealthnetwork.com/drugs/valbenazine-tosylate
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Valbenazine Tosylate?

Valbenazine Tosylate (brand name: Ingrezza) is a vesicular monoamine transporter 2 (vmat2) inhibitor. It is prescribed to treat tardive dyskinesia. Across the United States, 7,000 doctors prescribe Valbenazine to approximately 3,000 Medicare patients.

## Brand names

Ingrezza

## Indications

Valbenazine Tosylate is primarily prescribed for the treatment of tardive dyskinesia.

## Conditions treated

- [Tardive Dyskinesia](https://ourhealthnetwork.com/conditions/tardive-dyskinesia)

## Mechanism of action

The mechanism of action of valbenazine for the treatment of tardive dyskinesia and chorea in patients with Huntington’s disease is unclear, but is thought to be mediated through the reversible inhibition of vesicular monoamine transporter 2 (VMAT2), a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release.

## Drug classification

- Established Pharmacologic Class: vesicular monoamine transporter 2 (VMAT2) inhibitors
- Route of administration: ORAL

## Common side effects

schizoaffective disorder

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)